Retail News CRM

Tag: Kimia Farma

  • Indonesia’s Kimia Farma eyes Growth into Vietnam

    Indonesia’s Kimia Farma eyes Growth into Vietnam

    Indonesian state-owned pharmaceuticals firm Kimia Farma is considering expanding into Vietnam by acquiring a local company. The firm recently invested US$10.26 million in a Saudi Arabian firm, purchasing 60 percent of its shares and renaming it as Kimia Farma Dawaa.

    It is currently investigating Vietnamese regulations to discover whether or not it can own a majority stake in a local firm, a critical factor in securing its investment.

    “It depends on the regulation in the country,” said Kimia Farma finance director IGN Suharta Wijaya. “It the regulation is okay, we will enter the country this year.”

    “If the sales of each Kimia Farma outlet in the country is IDR1.5 billion ($104,877) per month, [the sales of an outlet of the Vietnamese company] could be IDR4 billion per month,” Wijaya added.

    Investment in the pharmaceutical industry is stepping up in Vietnam, with the announcement last week that Vietnam-focussed private equity firm Mekong Capital has issued funding to pharmacy chain Pharmacity.

    With 186 outlets retailing both traditional Vietnamese and Western medicines, Pharmacity is the country’s most widespread network of pharmaceutical products stores, with 1 million subscribers to its loyalty program. The firm is targeting 1000 outlets in Vietnam within two years.

    Reportedly, Kimia Farma is seeking to buy a chain with 400 outlets nationwide.

  • Kimia Farma to open 100 new outlets

    Kimia Farma to open 100 new outlets

    Kimia Farma Apotek, the operator of hundreds of dispensaries all over the country, will open 100 more dispensary outlets this year. The subsidiary of the state owned pharmaceutical company Kimia Farma said the new outlets would bring the total number of the companys dispensaries to 1,000 units this year.

    Chief Executive of Kimia Farma Apotek Imam Fathorrahman said the management has set aside Rp20 billion for the plan to increase the number of its outlets.

    “Currently the company already has 900 dispensaries with sales valued at a round Rp1.3 trillion last year,” Imam said here on Sunday.

    He said to coincide with its 14th anniversary in January, Kimia Farma Apotek will start entering the market of e-commerce.

    “Holders of smart phones have reached 126 percent of the total population and internet owners around 52 percent. This is an extraordinarily big e-commerce market,” he said.

    In the first phase, the company will eye the Jabodetabek (Greater Jakarta) market and cooperate with order shopping service between Go-Mart.

    “In principle through this service we could be accessed by customers in the Jabodetabek area, Bandung, Surabaya, Bali, and Makassar with more than 250 selected locations of our dispensaries,” he said.

    The digital service, however, is only for non-ethical medicines that could be sold without doctors prescription.

    “This access has become a requirement . People dont have to go to dispensary for cosmetics and drugs that could be bought without doctor prescription,” he said.

    Lees ook:

    Lees ook:

  • Kimia Farma builds pharmaceutical raw material factory

    Kimia Farma builds pharmaceutical raw material factory

    In cooperation with Sungwun Pharmacopia of South Korea, Indonesias state-owned pharmaceutical company PT Kimia Farma will build the first factory for pharmaceutical raw materials to meet the needs of medicine producers in the country.

    The construction of the pharmaceutical factory was inaugurated on Monday by Health Minister Nila F Moeloek, in the company of Kimia Farma President Director Rusdi Rosman, Food and Drug Regulatory Agency (BPOM) Chief Penny Lukito, and House Commission-IX Chairman Dede Yusuf.

    Rusdi Rosman said the factory, located at the Lippo industrial area in Cikarang, Bekasi, will be built in stages on a six-hectare plot of land and at a cost of Rp132 billion.

    In building the first factory for pharmaceutical raw materials, Kimia Farma will cooperate with Sungwun Pharmacopia Co. Ltd, because of their experience in producing raw materials for medicines.

    Further, the Kimia Farma president director noted that the factory will be built in accordance with the standard of Good Manufacturing Practice (GMP) and is expected to be completed by the end of 2017, while the selling of Active Pharmaceutical Raw Materials (API) is planned to begin in early 2018.

    Rusdi noted that the factory will produce eight types of raw materials, including Simvastatin, Atorvastatin, Rosuvastatin, Pantoprazole, Esomeprazole, Rabeprazole, Clopidogrel and Sarpogrelate, with a production capacity of 30 tons per year.

    Production of the raw materials is to meet 100 percent of the needs of the pharmaceutical industry in Indonesia, as well as for market export.

    Kimia Farma will also manufacture seven types of raw materials that can be used for cosmetics and dietary supplements, and to be exported to Korea, Japan and America.

    Lees ook: